Ligand Reports Second Quarter 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Wall St futures tick higher as oil retreats ahead of inflation data
- Oil falls on weaker demand outlook and higher US stocks
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Birkenstock surges on revenue beat, higher full-year outlook
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Deutsche Bank Downgrades Ligand Pharma (LGND) to Sell
August 5, 2016 6:45 AM EDTDeutsche Bank downgraded Ligand Pharma (NASDAQ: LGND) from Hold to Sell with a price target of $110.00 (from $104.00). The downgrade was tied to valuation.
Analyst Gregg Gilbert said, "Our model and $110 target factor in continued growth for key royalty drivers (particularly AMGNs Kyprolis and Novartis Promacta), growth in technology deals (tied to Captisol and other platforms), and launches of new... More
Ligand Pharma (LGND) Tops Q2 EPS by 10c; Affirms FY16 Outlook
August 4, 2016 8:56 AM EDTLigand Pharma (NASDAQ: LGND) reported Q2 EPS of $0.50, $0.10 better than the analyst estimate of $0.40. Revenue for the quarter came in at $19.5 million versus the consensus estimate of $18.12 million.
The Company affirms expectations for full-year 2016 total revenues to be between $115 million and $119... More
